For this reason, some pragmatic trials testing the use of immunotherapy in triple-negative BC (e.g., A-BRAVE trial, TONIC trial)10,11 have in fact applied a 10% threshold to define ER-positivity. The gene discussed is ESR1; the disease is breast cancer.